Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 3
2006 3
2007 1
2008 3
2009 2
2010 3
2011 3
2012 10
2013 5
2014 8
2015 7
2016 9
2017 13
2018 5
2019 9
2020 9
2021 8
2022 4
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation to analyze extracellular viral markers.
Kitagawa K, Kim KS, Iwamoto M, Hayashi S, Park H, Nishiyama T, Nakamura N, Fujita Y, Nakaoka S, Aihara K, Perelson AS, Allweiss L, Dandri M, Watashi K, Tanaka Y, Iwami S. Kitagawa K, et al. Among authors: dandri m. PLoS Comput Biol. 2024 Mar 11;20(3):e1011238. doi: 10.1371/journal.pcbi.1011238. eCollection 2024 Mar. PLoS Comput Biol. 2024. PMID: 38466770 Free PMC article.
Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice.
Lempp FA, Volz T, Cameroni E, Benigni F, Zhou J, Rosen LE, Noack J, Zatta F, Kaiser H, Bianchi S, Lombardo G, Jaconi S, Vincenzetti L, Imam H, Soriaga LB, Passini N, Belnap DM, Schulze A, Lütgehetmann M, Telenti A, Cathcart AL, Snell G, Purcell LA, Hebner CM, Urban S, Dandri M, Corti D, Schmid MA. Lempp FA, et al. Among authors: dandri m. J Hepatol. 2023 Nov;79(5):1129-1138. doi: 10.1016/j.jhep.2023.07.003. Epub 2023 Jul 17. J Hepatol. 2023. PMID: 37459920 Free article.
Non-organ-specific autoantibodies with unspecific patterns are a frequent para-infectious feature of chronic hepatitis D.
Hermanussen L, Lampalzer S, Bockmann JH, Ziegler AE, Piecha F, Dandri M, Pischke S, Haag F, Lohse AW, Lütgehetmann M, Weiler-Normann C, Zur Wiesch JS. Hermanussen L, et al. Among authors: dandri m. Front Med (Lausanne). 2023 Jun 14;10:1169096. doi: 10.3389/fmed.2023.1169096. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37387781 Free PMC article.
Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation for analyzing extracellular viral markers.
Kitagawa K, Kim KS, Iwamoto M, Hayashi S, Park H, Nishiyama T, Nakamura N, Fujita Y, Nakaoka S, Aihara K, Perelson AS, Allweiss L, Dandri M, Watashi K, Tanaka Y, Iwami S. Kitagawa K, et al. Among authors: dandri m. bioRxiv [Preprint]. 2023 Jun 7:2023.06.06.543822. doi: 10.1101/2023.06.06.543822. bioRxiv. 2023. PMID: 37333409 Free PMC article. Updated. Preprint.
A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
Anolli MP, Degasperi E, Allweiss L, Sangiovanni A, Maggioni M, Scholtes C, Oberhardt V, Neumann-Haefelin C, Dandri M, Zoulim F, Lampertico P. Anolli MP, et al. Among authors: dandri m. J Hepatol. 2023 Jan 3:S0168-8278(22)03475-4. doi: 10.1016/j.jhep.2022.12.023. Online ahead of print. J Hepatol. 2023. PMID: 36931396
Strain-specific responsiveness of hepatitis D virus to interferon-alpha treatment.
Giersch K, Perez-Gonzalez P, Hendricks L, Goldmann N, Kolbe J, Hermanussen L, Bockmann JH, Volz T, Volmari A, Allweiss L, Petersen J, Glebe D, Lütgehetmann M, Dandri M. Giersch K, et al. Among authors: dandri m. JHEP Rep. 2023 Jan 24;5(4):100673. doi: 10.1016/j.jhepr.2023.100673. eCollection 2023 Apr. JHEP Rep. 2023. PMID: 36908749 Free PMC article.
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.
Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin IG, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp FA, Port K, Haag M, Schwab M, Zur Wiesch JS, Cornberg M, Haefeli WE, Dandri M, Alexandrov A, Urban S. Wedemeyer H, et al. Among authors: dandri m. Lancet Infect Dis. 2023 Jan;23(1):117-129. doi: 10.1016/S1473-3099(22)00318-8. Epub 2022 Sep 13. Lancet Infect Dis. 2023. PMID: 36113537 Clinical Trial.
100 results